Study for Subjects with Moderate to Severe Crohn's Disease M-13, Using Investigative Medication

What we are studying

The purpose of this study is to evaluate the effect and safety of different doses of ABT-494 and to assess how drug is absorbed, distributed, and eliminated in the body over time of ABT-494 in subjects with moderate to severe Crohn's Disease. Some subjects will receive ABT-494 and some subjects will receive placebo. This means you could receive inactive drug.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • Hispanic or Latino
  • Ages 18 - 75

Eligibility Criteria

  • Diagnosed with active moderate to severe Crohn's Disease for at least 90 days
  • May have symptoms such as abdominal pain and diarrhea.

What is involved

  • 12 visits
  • Blood draws
  • Questionnaires
  • Medication administration at visit

Compensation

50.00 per visit. Paid by check at end of study or early withdrawal.

Contact Information

Study Coordinator
Barbara Lasater
Email
blasater@wakehealth.edu
Phone
336-713-7319
Principal Investigator
Richard S Bloomfeld, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.